相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
Alexander M. M. Eggermont et al.
LANCET ONCOLOGY (2015)
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Targeting CD4+ T-Helper Cells Improves the Induction of Antitumor Responses in Dendritic Cell-Based Vaccination
Erik H. J. G. Aarntzen et al.
CANCER RESEARCH (2013)
Therapeutic Lymph Node Dissection in Melanoma: Different Prognosis for Different Macrometastasis Sites?
K. P. Wevers et al.
ANNALS OF SURGICAL ONCOLOGY (2012)
Skin-Test Infiltrating Lymphocytes Early Predict Clinical Outcome of Dendritic Cell-Based Vaccination in Metastatic Melanoma
Erik H. J. G. Aarntzen et al.
CANCER RESEARCH (2012)
Vaccination with mRNA-Electroporated Dendritic Cells Induces Robust Tumor Antigen-Specific CD4+ and CD8+ T Cells Responses in Stage III and IV Melanoma Patients
Erik H. J. G. Aarntzen et al.
CLINICAL CANCER RESEARCH (2012)
Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial
Bryan H. Burmeister et al.
LANCET ONCOLOGY (2012)
Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used
W. Joost Lesterhuis et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
Route of Administration Modulates the Induction of Dendritic Cell Vaccine-Induced Antigen-Specific T Cells in Advanced Melanoma Patients
W. Joost Lesterhuis et al.
CLINICAL CANCER RESEARCH (2011)
gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma
Douglas J. Schwartzentruber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Multivariate Analysis of Prognostic Factors Among 2,313 Patients With Stage III Melanoma: Comparison of Nodal Micrometastases Versus Macrometastases
Charles M. Balch et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The Benefits of Adjuvant. Radiation Therapy After Therapeutic Lymphadenectomy for Clinically Advanced, High-Risk, Lymph Node-Metastatic Melanoma
Shefali Agrawal et al.
CANCER (2009)
Polyinosinic polycytidylic acid prevents efficient antigen expression after mRNA electroporation of clinical grade dendritic cells
Danita H. Schuurhuis et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Melanoma epidemiology and trends
Claus Garbe et al.
CLINICS IN DERMATOLOGY (2009)
Final Version of 2009 AJCC Melanoma Staging and Classification
Charles M. Balch et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Spontaneous regression of metastases from melanoma: review of the literature
Louise Vennegaard Kalialis et al.
MELANOMA RESEARCH (2009)
Dendritic cell vaccines in melanoma: From promise to proof?
W. J. Lesterhuis et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2008)
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma:: final results of EORTC 18991, a randomised phase III trial
Alexander M. M. Eggermont et al.
LANCET (2008)
Multivariable analysis comparing outcome after sentinel node biopsy or therapeutic lymph node dissection in patients with melanoma
A. C. J. van Akkooi et al.
BRITISH JOURNAL OF SURGERY (2007)
Taking dendritic cells into medicine
Ralph M. Steinman et al.
NATURE (2007)
Failure at the effector phase: Immune barriers at the level of the melanoma tumor microenvironment
Thomas F. Gajewski
CLINICAL CANCER RESEARCH (2007)
Morbidity and prognosis after therapeutic lymph node dissections for malignant melanoma
A. C. J. van Akkooi et al.
EJSO (2007)
Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma
S Verma et al.
CANCER (2006)
Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome
IJM de Vries et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Dendritic cell immunotherapy: mapping the way
CG Figdor et al.
NATURE MEDICINE (2004)
Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma
MB Lens et al.
BRITISH JOURNAL OF DERMATOLOGY (2004)
Does adjuvant interferon-α for high-risk melanoma provide a worthwhile benefit?: A meta-analysis of the randomised trials
K Wheatley et al.
CANCER TREATMENT REVIEWS (2003)
Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: Results of a randomized trial
P Hersey et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Large-scale generation of mature monocyte-derived dendritic cells for clinical application in cell factories™
TG Berger et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2002)
Prolonged survival of patients receiving active immunotherapy with canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes
DL Morton et al.
ANNALS OF SURGERY (2002)
Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system
CM Balch et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma
CM Balch et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
分享论文
